- Home
- INBX vs PRME Comparison
INBX vs PRME Comparison
Compare INBX & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INBX
- PRME
- Stock Information
- Founded
- INBX 2010
- PRME 2019
- Country
- INBX United States
- PRME United States
- Employees
- INBX N/A
- PRME N/A
- Industry
- INBX Biotechnology: Pharmaceutical Preparations
- PRME Medicinal Chemicals and Botanical Products
- Sector
- INBX Health Care
- PRME Health Care
- Exchange
- INBX Nasdaq
- PRME Nasdaq
- Market Cap
- INBX 178.5M
- PRME 191.7M
- IPO Year
- INBX 2020
- PRME 2022
- Fundamental
- Price
- INBX $21.60
- PRME $4.04
- Analyst Decision
- INBX Hold
- PRME Buy
- Analyst Count
- INBX 1
- PRME 6
- Target Price
- INBX N/A
- PRME $9.38
- AVG Volume (30 Days)
- INBX 148.3K
- PRME 5.8M
- Earning Date
- INBX 08-12-2025
- PRME 08-12-2025
- Dividend Yield
- INBX N/A
- PRME N/A
- EPS Growth
- INBX N/A
- PRME N/A
- EPS
- INBX 111.58
- PRME N/A
- Revenue
- INBX $200,000.00
- PRME $3,846,000.00
- Revenue This Year
- INBX N/A
- PRME $126.92
- Revenue Next Year
- INBX N/A
- PRME $87.32
- P/E Ratio
- INBX $0.19
- PRME N/A
- Revenue Growth
- INBX N/A
- PRME 550.76
- 52 Week Low
- INBX $10.80
- PRME $1.11
- 52 Week High
- INBX $25.29
- PRME $5.62
- Technical
- Relative Strength Index (RSI)
- INBX 54.33
- PRME 56.10
- Support Level
- INBX $20.84
- PRME $3.72
- Resistance Level
- INBX $25.29
- PRME $5.15
- Average True Range (ATR)
- INBX 1.84
- PRME 0.46
- MACD
- INBX -0.41
- PRME -0.15
- Stochastic Oscillator
- INBX 17.17
- PRME 31.93
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.